2.50Open2.50Pre Close0 Volume40 Open Interest2.50Strike Price0.00Turnover1049.49%IV2.04%PremiumDec 20, 2024Expiry Date2.40Intrinsic Value100Multiplier4DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.8771Delta0.0357Gamma1.61Leverage Ratio-0.1373Theta0.0002Rho1.41Eff Leverage0.0011Vega
Aldeyra Therapeutics Stock Discussion
Larger Image: tradingview.com...
$Aldeyra Therapeutics (ALDX.US)$
NEWS
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Positive
Enrollment of the first patient in the Phase 3 clinical trial for reproxalap indicates progress in Aldeyra Therapeutics' efforts to address dry eye disease.
Potential resubmission of the NDA for reproxalap in the second half of 2024 demonstrates the company's commitment to advancing in...
No comment yet